Tharimmune, Inc.
THARNASDAQHealthcare
$3.54
+$0.22(+6.63%)
Market Cap$139935658
P/E Ratio—
52W High$9.08
52W Low$0.952
Tharimmune, Inc. (THAR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
THAR · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 31, 2026EPS Actual
-$0.79
Est. -$0.42 · -88.1%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 31, 2026
After Market Close
▼ Miss EPS
THAR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Jun 3, 2026 | — | — | — | — | — | — |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$0.42 | -$0.79 | -88.1% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.43 | -$0.34 | +20.9% | — | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.58 | -$0.64 | -10.3% | — | — | — |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.84 | -$0.99 | -17.9% | — | — | — |
| ▼ Q1 FY2025 | Mar 25, 2025 | -$1.53 | -$2.02 | -32.0% | — | — | — |
| — Q4 FY2024 | Nov 7, 2024 | — | -$2.45 | — | — | — | — |
| — Q3 FY2024 | Aug 9, 2024 | — | -$2.42 | — | — | — | — |
Q2 FY2026
Jun 3, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$0.79
EPS Est.
-$0.42
EPS Surpr.
-88.1%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$0.43
EPS Surpr.
+20.9%
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.64
EPS Est.
-$0.58
EPS Surpr.
-10.3%
Revenue
—
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.99
EPS Est.
-$0.84
EPS Surpr.
-17.9%
Revenue
—
Q1 FY2025
Mar 25, 2025Miss
EPS Actual
-$2.02
EPS Est.
-$1.53
EPS Surpr.
-32.0%
Revenue
—
Q4 FY2024
Nov 7, 2024
EPS Actual
-$2.45
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 9, 2024
EPS Actual
-$2.42
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Q3 FY2025 | $-0.43 | $-0.43 | $-0.43 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 31, 2026 | -88.1% | $3.08 | $3.27 | +6.17% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +20.9% | $3.30 | $3.22 | -2.42% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -10.3% | $1.32 | $1.32 | +0.00% |
| ▼ Q2 FY2025 | May 12, 2025 | -17.9% | $1.51 | $1.56 | +3.31% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -32.0% | $1.53 | $1.46 | -4.58% |
| — Q4 FY2024 | Nov 7, 2024 | — | $2.80 | $2.43 | -13.21% |
| — Q3 FY2024 | Aug 9, 2024 | — | $2.90 | $2.93 | +1.03% |
| — Q2 FY2024 | May 9, 2024 | — | $6.14 | $6.15 | +0.16% |
Q1 FY2026+6.17%
Report Date
Mar 31, 2026
EPS Beat/Miss
-88.1%
Price Before
$3.08
Price After
$3.27
Q4 FY2025-2.42%
Report Date
Nov 12, 2025
EPS Beat/Miss
+20.9%
Price Before
$3.30
Price After
$3.22
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
-10.3%
Price Before
$1.32
Price After
$1.32
Q2 FY2025+3.31%
Report Date
May 12, 2025
EPS Beat/Miss
-17.9%
Price Before
$1.51
Price After
$1.56
Q1 FY2025-4.58%
Report Date
Mar 25, 2025
EPS Beat/Miss
-32.0%
Price Before
$1.53
Price After
$1.46
Q4 FY2024-13.21%
Report Date
Nov 7, 2024
EPS Beat/Miss
—
Price Before
$2.80
Price After
$2.43
Q3 FY2024+1.03%
Report Date
Aug 9, 2024
EPS Beat/Miss
—
Price Before
$2.90
Price After
$2.93
Q2 FY2024+0.16%
Report Date
May 9, 2024
EPS Beat/Miss
—
Price Before
$6.14
Price After
$6.15
Avg Beat Reaction-2.42%
Avg Miss Reaction+1.23%
Beat Rate1 / 8 quarters
Largest Move-13.21% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: THAR ends December
Tharimmune, Inc. (THAR) most recently reported earnings on March 31, 2026 for Q1 FY2026, posting EPS of $-0.79 — missing the analyst consensus of $-0.42 by -88.1%. The next THAR earnings date is expected around September 1, 2026.
Each quarter, investors track THAR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. THAR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
THAR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
THAR earnings · 5 questionsTharimmune, Inc.'s next earnings report is expected around September 1, 2026. THAR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; THAR historically reports after market close (AMC).
THAR earnings datewhen is THAR earningsTHAR next earnings datewhen does THAR report earningsTHAR earnings calendar
▸ Source: FMP · Tharimmune, Inc. SEC filings · US GAAP · Tharimmune, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026